210 related articles for article (PubMed ID: 35671049)
21. Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy.
Kim BR; Kim J; Lee JE; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):39. PubMed ID: 32196098
[TBL] [Abstract][Full Text] [Related]
22. Ceruloplasmin regulating fibrosis in orbital fibroblasts provides a novel therapeutic target for Graves' orbitopathy.
Cao J; Qi X; Wang N; Chen Y; Xie B; Ma C; Chen Z; Xiong W
J Endocrinol Invest; 2023 Oct; 46(10):2005-2016. PubMed ID: 36849849
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
24. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
[TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy.
Yoon JS; Chae MK; Lee SY; Lee EJ
Br J Ophthalmol; 2012 Aug; 96(8):1117-21. PubMed ID: 22661653
[TBL] [Abstract][Full Text] [Related]
26. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
[TBL] [Abstract][Full Text] [Related]
27. Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy.
Wang X; Ye H; Yang S; Sha X; Wang X; Zhang T; Chen R; Xiao W; Yang H
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563653
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves' Ophthalmopathy through the Regulation of FoxO3a Signaling.
Wei YH; Liao SL; Wang CC; Wang SH; Tang WC; Yang CH
Mediators Inflamm; 2021; 2021():8888913. PubMed ID: 33542676
[TBL] [Abstract][Full Text] [Related]
29. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
[No Abstract] [Full Text] [Related]
30. Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves' orbital fibroblasts.
Lee SJ; Kim J; Ko J; Lee EJ; Koh HJ; Yoon JS
PLoS One; 2018; 13(12):e0209583. PubMed ID: 30576385
[TBL] [Abstract][Full Text] [Related]
31. Molecular biomarkers of Graves' ophthalmopathy.
Longo CM; Higgins PJ
Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.
Seo Y; Chae MK; Han SA; Lee EJ; Lee JH; Yoon JS
Inflamm Res; 2017 Jun; 66(6):535-545. PubMed ID: 28364200
[TBL] [Abstract][Full Text] [Related]
33. Cell density-dependent stimulation of PAI-1 and hyaluronan synthesis by TGF-β in orbital fibroblasts.
Galgoczi E; Jeney F; Gazdag A; Erdei A; Katko M; Nagy DM; Ujhelyi B; Steiber Z; Gyory F; Berta E; Nagy EV
J Endocrinol; 2016 May; 229(2):187-96. PubMed ID: 26979769
[TBL] [Abstract][Full Text] [Related]
34. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves' orbitopathy: clinical implications.
Pawlowski P; Reszec J; Eckstein A; Johnson K; Grzybowski A; Chyczewski L; Mysliwiec J
Mediators Inflamm; 2014; 2014():412158. PubMed ID: 25309050
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.
Hai YP; Lee ACH; Frommer L; Diana T; Kahaly GJ
J Endocrinol Invest; 2020 Feb; 43(2):123-137. PubMed ID: 31538314
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves' orbitopathy by repressing interleukin-2-inducible T-cell kinase.
Choi YJ; Kim C; Choi EW; Lee SH; Chae MK; Jun HO; Kim BY; Yoon JS; Jang SY
PLoS One; 2022; 17(8):e0270416. PubMed ID: 35980936
[TBL] [Abstract][Full Text] [Related]
37. Gypenosides Protect Orbital Fibroblasts in Graves Ophthalmopathy via Anti-Inflammation and Anti-Fibrosis Effects.
Li H; Ma C; Liu W; He J; Li K
Invest Ophthalmol Vis Sci; 2020 May; 61(5):64. PubMed ID: 32462203
[TBL] [Abstract][Full Text] [Related]
38. Macrophage-Orbital Fibroblast Interaction and Hypoxia Promote Inflammation and Adipogenesis in Graves' Orbitopathy.
Görtz GE; Philipp S; Bruderek K; Jesenek C; Horstmann M; Henning Y; Oeverhaus M; Daser A; Bechrakis NE; Eckstein A; Brandau S; Berchner-Pfannschmidt U
Endocrinology; 2022 Dec; 164(2):. PubMed ID: 36477465
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of human orbital fibroblasts cultivated from intraconal, nasal and central adipose tissues.
Kim JA; Ahn D; Kim BY; Choi YJ; Shin HJ; Jang SY
Br J Ophthalmol; 2021 Feb; 105(2):290-296. PubMed ID: 31488432
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
